Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) disclosed a repurchase of 153,200 H-shares on 9 July 2026, executed on the Hong Kong Stock Exchange.

The transaction was completed at prices ranging from HKD 19.07 to HKD 19.87 per share, with a volume-weighted average repurchase price of HKD 19.53. Total consideration amounted to HKD 2.99 million.

Following the buyback, the company’s issued share capital (excluding treasury shares) fell by 0.10% to 153.74 million shares. Treasury shares on hand increased to 583,400, while total issued shares remained unchanged at 154.33 million.

The purchase forms part of the mandate approved on 26 May 2026, which authorises repurchases of up to 15.43 million shares. Cumulative buybacks under this mandate now stand at 583,400 shares, representing 0.38% of the authorised limit and 0.38% of issued shares on the mandate date.

Under Hong Kong listing rules, Bao Pharma is subject to a moratorium on new share issues or treasury-share sales until 8 August 2026.